AI Engines For more Details: Perplexity Kagi Labs You
Hair Growth Stimulation: Minoxidil works by widening hair follicles and prolonging the growth phase of hair, leading to increased hair growth and improved hair density. It is effective in treating male-pattern baldness (androgenetic alopecia) and female-pattern hair loss.
Treatment of Alopecia: Minoxidil is also used to treat other forms of hair loss, such as alopecia areata, an autoimmune condition that causes patchy hair loss on the scalp and sometimes other areas of the body. It may help stimulate hair regrowth in affected areas.
Topical Application: Minoxidil is typically applied topically to the scalp in either liquid or foam formulation. It should be applied directly to the affected areas of the scalp once or twice daily, as directed by a healthcare professional.
Side Effects: Common side effects of minoxidil include scalp irritation, itching, dryness, and redness. Some individuals may experience temporary hair shedding when they first start using minoxidil, but this usually subsides within a few weeks. Rare but serious side effects may include allergic reactions, chest pain, rapid heartbeat, dizziness, and swelling of the face or extremities. If any of these symptoms occur, medical attention should be sought immediately.
Systemic Effects: While minoxidil is primarily used as a topical medication for hair loss, it can also be absorbed systemically through the skin. In some cases, systemic absorption of minoxidil may lead to side effects such as low blood pressure (hypotension), fluid retention, and heart palpitations. Individuals with cardiovascular conditions should use minoxidil with caution and under the supervision of a healthcare provider.
Duration of Treatment: Minoxidil is a long-term treatment for hair loss, and its effects may take several months to become apparent. Continued use of minoxidil is necessary to maintain hair growth benefits. If treatment is discontinued, any hair that has been gained or preserved may gradually be lost over time.
Contraindications: Minoxidil should not be used by individuals who are allergic to the medication or any of its ingredients. It is also not recommended for use by pregnant or breastfeeding women unless specifically instructed by a healthcare provider.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
Acne | 0.6 | 0.6 | |
ADHD | 0.5 | 0.6 | -0.2 |
Allergic Rhinitis (Hay Fever) | 0.9 | 0.1 | 8 |
Allergies | 1.4 | 0.6 | 1.33 |
Allergy to milk products | 1 | 0.9 | 0.11 |
Alopecia (Hair Loss) | 0.3 | 0.3 | |
Alzheimer's disease | 2.5 | 2.4 | 0.04 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0.1 | 10 |
Ankylosing spondylitis | 1.3 | 0.3 | 3.33 |
Anorexia Nervosa | 0.6 | -0.6 | |
Antiphospholipid syndrome (APS) | 0.2 | 0.3 | -0.5 |
Asthma | 0.7 | 0.3 | 1.33 |
Atherosclerosis | 0.9 | 0.9 | |
Atrial fibrillation | 0.8 | 1.2 | -0.5 |
Autism | 2.1 | 1.9 | 0.11 |
Autoimmune Disease | 0.6 | 0.6 | |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 0.1 | 0.1 | |
Bipolar Disorder | 1.5 | 0.6 | 1.5 |
Brain Trauma | 0.3 | 0.3 | 0 |
Breast Cancer | 0.4 | 0.4 | |
Cancer (General) | 0.5 | -0.5 | |
Carcinoma | 1.7 | 0.6 | 1.83 |
Celiac Disease | 0.7 | 0.6 | 0.17 |
Cerebral Palsy | 0.3 | 0.3 | 0 |
Chronic Fatigue Syndrome | 1.2 | 1.5 | -0.25 |
Chronic Kidney Disease | 2 | 0.9 | 1.22 |
Chronic Lyme | 0 | 0.3 | 0 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.3 | 0.33 |
Chronic Urticaria (Hives) | 0.7 | 0.3 | 1.33 |
Coagulation / Micro clot triggering bacteria | 0.7 | 0.7 | |
Cognitive Function | 0.6 | 0.6 | |
Colorectal Cancer | 1.3 | 0.7 | 0.86 |
Constipation | 0.9 | 0.1 | 8 |
Coronary artery disease | 1 | 0.8 | 0.25 |
COVID-19 | 2 | 2.3 | -0.15 |
Crohn's Disease | 2.4 | 1.1 | 1.18 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 0.7 | 0.3 | 1.33 |
d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
deep vein thrombosis | 1.3 | 0.3 | 3.33 |
Depression | 3 | 2.1 | 0.43 |
Eczema | 0.6 | 0.3 | 1 |
Endometriosis | 1.3 | 0.4 | 2.25 |
Epilepsy | 1.5 | 0.3 | 4 |
erectile dysfunction | 0.9 | 0.9 | |
Fibromyalgia | 0.3 | 0.8 | -1.67 |
Functional constipation / chronic idiopathic constipation | 2 | 1.4 | 0.43 |
gallstone disease (gsd) | 1 | 1 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
Generalized anxiety disorder | 1.6 | 0.6 | 1.67 |
Gout | 1 | 0.3 | 2.33 |
Graves' disease | 0.6 | 0.9 | -0.5 |
Gulf War Syndrome | 0.3 | 0.4 | -0.33 |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 0.6 | 0.6 | 0 |
Heart Failure | 1.3 | 1.3 | |
Hidradenitis Suppurativa | 0.6 | 0.6 | |
High Histamine/low DAO | 0.1 | 0.1 | |
hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
hyperglycemia | 0.7 | 0.3 | 1.33 |
Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
hypersomnia | 0.6 | -0.6 | |
hypertension (High Blood Pressure | 1.2 | 1.3 | -0.08 |
Hypothyroidism | 0.6 | -0.6 | |
Hypoxia | 1 | 0 | 0 |
IgA nephropathy (IgAN) | 0.6 | 0.6 | 0 |
Inflammatory Bowel Disease | 2.5 | 1.5 | 0.67 |
Insomnia | 0.6 | 0.3 | 1 |
Intelligence | 0.7 | 0 | 0 |
Intracranial aneurysms | 0.3 | 0.6 | -1 |
Irritable Bowel Syndrome | 2 | 1.3 | 0.54 |
ischemic stroke | 0.4 | 0.9 | -1.25 |
Liver Cirrhosis | 2.1 | 1 | 1.1 |
Long COVID | 2.6 | 1.4 | 0.86 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 1.4 | 1.4 | |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.6 | 0.3 | 1 |
ME/CFS with IBS | 0.8 | -0.8 | |
ME/CFS without IBS | 0.3 | 0.3 | 0 |
Menopause | 0.5 | 0.5 | |
Metabolic Syndrome | 3.4 | 1.1 | 2.09 |
Mood Disorders | 2.8 | 2.3 | 0.22 |
Multiple Sclerosis | 1.3 | 0.9 | 0.44 |
myasthenia gravis | 0.6 | 0.6 | |
neuropathic pain | 0.3 | 0.3 | 0 |
Neuropathy (all types) | 0.3 | 0.7 | -1.33 |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 0.6 | 2 |
NonCeliac Gluten Sensitivity | 0.9 | 0.3 | 2 |
Obesity | 2.5 | 1.4 | 0.79 |
obsessive-compulsive disorder | 1.7 | 0.6 | 1.83 |
Osteoarthritis | 0.9 | 0.3 | 2 |
Osteoporosis | 1.2 | 0.3 | 3 |
Parkinson's Disease | 2.5 | 1.5 | 0.67 |
Polycystic ovary syndrome | 1.4 | 0.6 | 1.33 |
Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
Premenstrual dysphoric disorder | 0.3 | 0.3 | |
primary biliary cholangitis | 0.3 | -0.3 | |
Primary sclerosing cholangitis | 0.3 | 0.3 | 0 |
Psoriasis | 0.5 | 0.6 | -0.2 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.2 | 1.1 | 1 |
Schizophrenia | 1.4 | 0.6 | 1.33 |
scoliosis | 0.4 | 0.3 | 0.33 |
Sjögren syndrome | 0.6 | 0.3 | 1 |
Sleep Apnea | 0.3 | 0.9 | -2 |
Slow gastric motility / Gastroparesis | 0.4 | 0.4 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | |
Stress / posttraumatic stress disorder | 0.4 | 0.9 | -1.25 |
Systemic Lupus Erythematosus | 2 | 2 | |
Tic Disorder | 0.3 | -0.3 | |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 2.2 | 0.3 | 6.33 |
Type 2 Diabetes | 3 | 1.2 | 1.5 |
Ulcerative colitis | 1.3 | 1.8 | -0.38 |
Unhealthy Ageing | 1.4 | 0.3 | 3.67 |
Vitiligo | 0.6 | 0.5 | 0.2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]